866-997-4948(US-Canada Toll Free)

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2014

Published By :

Global Markets Direct

Published Date : Nov 2014

Category :

Cancer

No. of Pages : 55 Pages

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2014

Summary

Global Markets Directs, Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2014, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview 6
Therapeutics Development 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis 8
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics under Development by Companies 9
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Products under Development by Companies 12
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development 13
INSYS Therapeutics, Inc. 13
Neotropix, Inc. 14
Novartis AG 15
Orphagen Pharmaceuticals, Inc. 16
Pfizer Inc. 17
Tekmira Pharmaceuticals Corp. 18
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ATR-101 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
axitinib - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
cintredekin besudotox - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
dovitinib lactate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NTX-010 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
TKM-PLK1 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Recent Pipeline Updates 43
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects 49
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products 50
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones 51
Featured News & Press Releases 51
Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma 51
Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1 51
Aug 12, 2013: Tekmira commences Phase I/II study of TKM-PLK1 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Tables
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2014 7
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by INSYS Therapeutics, Inc., H2 2014 13
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Neotropix, Inc., H2 2014 14
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Novartis AG, H2 2014 15
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2014 16
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Pfizer Inc., H2 2014 17
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics - Recent Pipeline Updates, H2 2014 43
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H2 2014 49
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H2 2014 50

List of Figures
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2014 7
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Top 10 Targets, H2 2014 20
Number of Products by Stage and Top 10 Targets, H2 2014 20
Number of Products by Top 10 Mechanism of Actions, H2 2014 22
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 22
Number of Products by Top 10 Routes of Administration, H2 2014 24
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 25
Number of Products by Top 10 Molecule Types, H2 2014 26
Number of Products by Stage and Top 10 Molecule Types, H2 2014 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *